This study is being conducted to evaluate how long people can stay in remission after stopping a specific type of treatment for Multiple Myeloma, which is a type of blood cancer that affects plasma cells in the bone marrow. The study focuses on patients who have had a significant reduction in their M-spike, a measurement of the abnormal protein produced by cancer cells in the blood. The medications being studied are elranatamab and teclistamab, which are known as BCMA-CD3 bispecific antibodies. These are specialized drugs designed to help the immune system find and attack the cancer cells.

The purpose of this study is to determine how long the disease remains inactive and how much time can pass without treatment after the medications are stopped. During the study, patients will receive the medication through a subcutaneous injection, which is a shot given into the fatty tissue just under the skin. Participants will be monitored to see if the cancer returns or if the response to the treatment lasts over time. Researchers will also look at how the medications affect overall survival and the frequency of side effects, such as infections, both during and after the treatment period.